Professor of Urology, University Conn
Urology
Dr. Peter C. Albertsen, MD
|
|
Give Review
Peter C. Albertsen, MD is an expert in the field of Urology. He attended Columbia University College of Physicians & Surgeons. Columbia University College of Physicians & Surgeons is a top medical college. Columbia University College of Physicians & Surgeons is ranked 8/52 in Research/PrimaryCare. He received 4 awards: "America's Top Doctors", "CMS Meaningful Use Stage 1 Certification", "America's Top Doctors for Cancer" and "Top MD". Peter Albertsen is also a published MD. He has 96 publication published. The most recent publication is: Surgery is possible: now let's prove its superior efficacy! He accepts all Medicare patients.
Publications
- Surgery is possible: now let's prove its superior efficacy!
- Does a positive margin always mandate adjuvant radiotherapy?
- Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.
- Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
- Bone complications among prostate Cancer survivors: long-term follow-up from the prostate Cancer outcomes study.
- Re: Relative Value of Race, Family History and Prostate Specific Antigen as Indications for Early Initiation of Prostate Cancer Screening: E. A. Vertosick, B. Y. Poon ...
- Influence of Age on Incident Diabetes and Cardiovascular Disease Among Prostate Cancer Survivors Receiving Androgen Deprivation Therapy.
- Better Survival After Curative Treatment for Screen-detected Prostate Cancer Compared with Clinical Diagnosis: A Real Effect or Lead-time Bias?
- Prediction of Long-term Other-cause Mortality in Men With Early-stage Prostate Cancer: Results From the Prostate Cancer Outcomes Study.
- The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research.
- Fifteen-Year Survival Outcomes Following Primary Androgen-Deprivation Therapy for Localized Prostate Cancer.
- Radical prostatectomy reduces prostate Cancer-specific mortality among men with intermediate-grade disease, but provides minimal benefit for men with low-grade and hig...
- Times, They Are a-Changing.
- Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist.
- Re: Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
- MRI before Prostate Biopsy-Yes or No?
- Adjuvant and salvage radiation therapy after Prostatectomy: american society for radiation oncology/american urological association guidelines.
- Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate Cancer.
- Early Detection of Prostate Cancer: AUA Guideline.
- Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Guideline.
- Mortality After Radical Prostatectomy or External Beam Radiotherapy for Localized Prostate Cancer.
- Long-term functional outcomes after treatment for localized prostate Cancer.
- Prostate specific antigen best practice statement: 2009 update.
- What is the risk posed by prostate Cancer?
- CRITICAL ROLE OF PROSTATE BIOPSY MORTALITY IN THE NUMBER OF YEARS OF LIFE GAINED AND LOST WITHIN A PROSTATE Cancer SCREENING PROGRAMME.
- How best to use our tools?
- The prostate Cancer conundrum revisited: Further insights.
- A tale of 2 perspectives: The clinician and the public health professional.
- Fake Innovation or the Real Deal?
- The Society of Urologic Oncology's reply to the US Preventative Services Task Force's recommendation on PSA testing.
- The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate Cancer in the medicare population.
- Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved.
- The impact of PSA testing frequency on prostate Cancer incidence and treatment in older men.
- Risk-Based Prostate Cancer Screening.
- Suitability of PSA-detected localised prostate Cancers for focal therapy: experience from the ProtecT study.
- The timing and extent of androgen deprivation therapy for prostate Cancer: weighing the clinical evidence.
- When is active surveillance the appropriate treatment for prostate Cancer?
- Words of wisdom. Re: active surveillance compared with initial treatment in men with low-risk prostate Cancer: a decision analysis.
- Impact of comorbidity on survival among men with localized prostate Cancer.
- Patterns and correlates of prostate Cancer treatment in older men.
- Trends in the treatment of localized prostate Cancer using supplemented Cancer registry data.
- Use and assessment of PSA in prostate Cancer.
- WHO International Consultation on Prostate Cancer: A summary.
- Further support for active surveillance in the management of low-volume, low-grade prostate Cancer.
- Diabetes mellitus and health-related quality of life in prostate Cancer: 5-year results from the Prostate Cancer Outcomes Study.
- Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate Cancer.
- Risk profiles and treatment patterns among men diagnosed as having prostate Cancer and a prostate-specific antigen level below 4.0 ng/ml.
- Treatment of localized prostate Cancer: when is active surveillance appropriate?
- Efficacy vs effectiveness in Prostate-specific antigen screening.
- The unintended burden of increased prostate Cancer detection associated with prostate Cancer screening and diagnosis.
- Does the benefit justify the risk?
- Regionalizing urologic Cancer care: appropriate health care policy?
- A statistical evaluation of rules for biochemical failure after radiotherapy in men treated for prostate Cancer.
- An iatrogenic confounding variable.
- Prostate Cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
- Lies, damn lies, and Cancer statistics.
- Measuring illness uncertainty in men undergoing active surveillance for prostate Cancer.
- Outcomes of localized prostate Cancer following conservative management.
- A 72-year-old man with localized prostate Cancer--14 years later.
- Personalized prediction of tumor response and Cancer progression on prostate needle biopsy.
- Androgen deprivation in prostate Cancer--step by step.
- First-year costs of treating prostate Cancer: estimates from SEER-Medicare data.
- Words of wisdom. Re: Radical prostatectomy versus watchful waiting in localized prostate Cancer: the Scandinavian Prostate Cancer Group-4 randomized trial.
- Use of 5alpha-reductase inhibitors for prostate Cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Gu...
- Use of 5-alpha-reductase inhibitors for prostate Cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice G...
- The treatment paradigm shifts again on prostate Cancer.
- A challenge to contemporary management of prostate Cancer.
- Screening, treatment, and prostate Cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up.
- Outcomes following active surveillance of men with localized prostate Cancer diagnosed in the prostate specific antigen era.
- Screening for Bladder cancer: theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease.
- Survival following primary androgen deprivation therapy among men with localized prostate Cancer.
- Should patients consider active surveillance?
- The face of high risk prostate Cancer.
- Prostate-Cancer mortality in the USA and UK in 1975-2004: an ecological study.
- Detecting trends in noisy data series: application to biomarker series.
- Should men over the age of 65 years receive PSA screening? Argument against.
- 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study.
- Active surveillance for early-stage prostate Cancer: review of the current literature.
- Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate Cancer.
- Secular trends in prostate Cancer mortality, incidence and treatment: England and Wales, 1975-2004.
- Should men with low-risk, localized prostate Cancer choose active surveillance or undergo a robotic prostatectomy?
- Predicting survival for men with clinically localized prostate Cancer: what do we need in contemporary practice?
- Patient outcomes and length of hospital stay after radical prostatectomy for prostate Cancer: analysis of hospital episodes statistics for England.
- Competing risks for patients with localized prostate Cancer.
- What do we really know about prostate Cancer?
- Commentary: occult prostate Cancer--imposter or the real deal?
- 13-year outcomes following treatment for clinically localized prostate Cancer in a population based cohort.
- Does radical prostatectomy provide a survival benefit as primary treatment for high-grade prostate Cancer?
- PSA and the conservative treatment of early prostate Cancer.
- PSA testing: public policy or private penchant?
- A charting tool for estimating the PSA doubling time in patients with prostate Cancer.
- Open to debate. The motion: there is evidence that prostate Cancer screening does more good than harm.
- What is the value of screening for prostate Cancer in the US?
- Clinical and physical determinants for toxicity of 125-I seed Prostate brachytherapy.
- The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples.
Schools
Columbia University College Of Physicians and Surgeons
Procedures Preformed
- Cystectomy
- Cystourethroscopy and Transurethral Resection of Bladder Neck
- Orchiectomy
- Prostate Removal
- View All
Conditions Treated
- Balanoposthitis
- Bladder Cancer
- Bladder Infection
- Bladder Stones
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
- Top MD
Education
-
Johns Hopkins University -
Beth Israel Deaconess Medical Center -
Columbia University College of Physicians & Surgeons
Hospital
-
Hartford Hospital
Drug Facts
| NPI NUMBER | 1811992639 | |
| NPPES Provider LastName | ALBERTSEN | |
| NPPES Provider FirstName | PETER | |
| NPPES Provider ZIPCode | 060300001 | |
| NPPES Provider State | CT | |
| Specialty Description | Urology | |
| Total Claim Count | 862.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1811992639 |
| Last Name Of The Provider | ALBERTSEN |
| First Name Of The Provider | PETER |
| View All |
Similar Doctors
|
|
Dr. John A. Taylor, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanton C. Honig, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Erica H. Lambert, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason E. Michaud, MD |
|
|
Dr. Cory D. Harris, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rafael S. Wurzel, MD |
|
|
Dr. JILL M. PETERS-GEE, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brendan M. Fox, MD
This Doctor is OpenDoctor Recommended.
|